Tsao Shih-Ming, Lin Hsiu-Chen, Lee Chun-Ming, Hsu Gwo-Jong, Chen Chih-Ming, Sun Wu, Liu Yung-Ching, Jang Tsrang-Neng, Cheng Yu-Jen, Lu Po-Liang, Chiang Ping-Chreng, Wang Lih-Shinn, Kung Hsiang-Chi, Chuang Yin-Ching, Shi Zhi-Yuan, Liu Jien-Wei, Huang Cheng-Hua, Lu Chin-Te, Liao Chun-Hsing, Hsueh Po-Ren
Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
Int J Antimicrob Agents. 2008 Nov;32 Suppl 3:S184-7. doi: 10.1016/S0924-8579(08)70025-6.
Tigecycline In-vitro Surveillance in Taiwan (TIST), initiated in 2006, is a nationwide surveillance programme designed to monitor longitudinally the in-vitro activity of tigecycline against commonly encountered resistant bacteria in Taiwan. This study, part of TIST-2006 study, aimed to compare the in-vitro activity of tigecycline against clinical isolates of Gram-positive bacteria. A total of 805 isolates of Gram-positive bacteria were collected from patients treated at 20 teaching hospitals. Minimum inhibitory concentrations (MICs) of tigecycline for these isolates were determined by the broth microdilution method according to the guidelines of the Clinical and Laboratory Standards Institute, and by the Etest as per the manufacturer's instructions. Susceptibility results were interpreted by the MIC criteria recommended by the US FDA. Agreement between the two methods was low: 80.7% for methicillin-resistant Staphylococcus aureus (MRSA), 27.2% for Streptococcus pneumoniae, 22.8% for other Streptococcus spp., and 30.8% for vancomycin-resistant E. faecium (VRE). There were no very major or major errors noted. Tigecycline exhibited excellent in-vitro activity against Gram-positive cocci, including MRSA, VRE, S. pneumoniae and other Streptococcus spp. isolates in Taiwan. Correlation between MIC values determined using the broth microdilution and Etest methods for these organisms was poor.
台湾替加环素体外监测（TIST）始于2006年，是一项全国性监测计划，旨在纵向监测替加环素对台湾常见耐药菌的体外活性。本研究作为TIST - 2006研究的一部分，旨在比较替加环素对革兰氏阳性菌临床分离株的体外活性。从20家教学医院接受治疗的患者中总共收集了805株革兰氏阳性菌分离株。根据临床和实验室标准协会的指南，采用肉汤微量稀释法，并按照制造商的说明使用Etest法测定替加环素对这些分离株的最低抑菌浓度（MIC）。药敏结果根据美国食品药品监督管理局推荐的MIC标准进行判读。两种方法之间的一致性较低：耐甲氧西林金黄色葡萄球菌（MRSA）为80.7%，肺炎链球菌为27.2%，其他链球菌属为22.8%，耐万古霉素屎肠球菌（VRE）为30.8%。未发现非常重大或重大错误。替加环素对台湾的革兰氏阳性球菌，包括MRSA、VRE、肺炎链球菌和其他链球菌属分离株表现出优异的体外活性。使用肉汤微量稀释法和Etest法测定的这些微生物的MIC值之间的相关性较差。
